Transgender Men and Transmasculine One-on-One and Group-Delivered Empowerment for Targeted HIV Reduction (TOGETHR) Study: Protocol for a Digital Factorial Randomized Controlled Trial
JMIR Research Protocols · 2025
DOI: 10.2196/76831 ↗At a glance
Randomisierte kontrollierte Studie in JMIR Research Protocols, 2025. Written by Sari L Reisner and 10 co-authors. Institution: Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, United States. Major MEDLINE topics: HIV Infections, Transgender Persons, Pre-Exposure Prophylaxis, Empowerment. Cited 1 times so far (Crossref); 103 references. The full text is freely available in PubMed Central. Funded by: NIMH NIH HHS.
Abstract (original language)
Background
In the United States, transgender men and transmasculine people who have sex with men (TMSM) face an increased risk of HIV and encounter unique barriers to HIV prevention services, including preexposure prophylaxis (PrEP). Peer-based, digitally delivered support interventions that address these barriers in 1-on-1 or small-group settings may be effective in increasing PrEP engagement.
Objective
This study aims to compare the efficacy of digitally delivered individual and small-group peer-based strategies for improving PrEP uptake and adherence among at-risk adult TMSM without HIV.
Methods
The Transmasculine One-on-One and Group Empowerment for Targeted HIV Reduction (TOGETHR) study was a digital, open-label, randomized 2×2 factorial trial (1:1:1:1 randomization) of peer-delivered HIV prevention strategies designed to increase PrEP engagement in 300 PrEP-indicated TMSM without HIV. Participants were randomized to 1 of 4 conditions: (A) standard of care (SOC) package (information and PrEP locator tools), (B) SOC + PrEP for TMSM (PrEP4T; individual peer-based HIV prevention intervention), (C) SOC + LifeSkills for TMSM (LS4TM; group peer-based HIV prevention intervention), or (D) SOC + PrEP4T and LS4TM (both individual and group interventions). Interventions were delivered over a 6-week period. The study enrolled adults 18 years or older who were “transgender men or transmasculine,” sexually active with 1 or more partners who had a penis and were assigned male sex at birth, living without HIV, behaviorally at risk for HIV acquisition, and residing in geographic hot spots identified in the US Ending the HIV Epidemic initiative.
Results
Study protocols and procedures were codeveloped with our community advisory board, including eligibility criteria, operationalization of geographic stratification, study branding, and detailed recruitment plans. Recruitment and enrollment began on April 1, 2024, and as of March 20, 2025, 103 TMSM had been enrolled. The median age was 26 (IQR 24-31) years. Among the 103 participants, 39 (37.9%) identified as Black, Indigenous, and People of Color, and 18 (17.5%) as Latine; 36 (35.0%) identified as “transgender man or trans man”; 31 (30.1%) as transmasculine; and 15 (14.6%) as nonbinary, genderqueer, or gender nonconforming. Additionally, 69 (67.0%) had at least a four-year college degree, and only 7 (6.8%) had no health insurance. Granger causality tests indicated that recruitment activities via social media (P=.006) and transgender-inclusive dating platforms (P=.02) were most effective and predicted higher baseline enrollment survey completion 2 weeks later. On March 21, 2025, the National Institutes of Health terminated the grant award, citing gender ideology and stating, “it is the policy of NIH not to prioritize such research programs.” Conclusions This study was part of a critical research pathway to identify effective strategies for preventing HIV acquisition in TMSM, a group traditionally underserved in HIV prevention, and to inform prevention packages that incorporate peer-delivered interventions. Strong engagement with the TMSM community was central to the study’s success and provided valuable insights for future HIV prevention research and practice. Trial Registration ClinicalTrials.gov NCT06182280; https://clinicaltrials.gov/ct2/show/NCT06182280 International Registered Report Identifier (IRRID) DERR1-10.2196/76831
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, United States.
- The Fenway Institute, Fenway Health, Boston, MA, United States.
- Drexel University, Philadelphia, United States.
- Department of Health, Behavior, and Society,, School of Public Health, Johns Hopkins University, Baltimore, United States.
- Queery Research Consulting, Glen Burnie, MD, United States.
- Department of Epidemiology, School of Public Health, Johns Hopkins University, Baltimore, United States.
ORCID profiles: Sari L Reisner, Ayden I Scheim, S Wilson Cole, Andrea L Wirtz, Tonia Poteat, Matthew J Mimiaga, Mark A Marzinke, Alek I Meyer, Kevin Smith, David R Pletta, Kenneth H Mayer
Funding
- NIMH NIH HHS
Cite
APA
Reisner, S. L., Scheim, A. I., Cole, S. W., Wirtz, A. L., Poteat, T., Mimiaga, M. J., Marzinke, M. A., Meyer, A. I., Smith, K., Pletta, D. R., & Mayer, K. H. (2025). Transgender Men and Transmasculine One-on-One and Group-Delivered Empowerment for Targeted HIV Reduction (TOGETHR) Study: Protocol for a Digital Factorial Randomized Controlled Trial. JMIR Research Protocols. https://doi.org/10.2196/76831
Vancouver
Reisner SL, Scheim AI, Cole SW, Wirtz AL, Poteat T, Mimiaga MJ, et al. Transgender Men and Transmasculine One-on-One and Group-Delivered Empowerment for Targeted HIV Reduction (TOGETHR) Study: Protocol for a Digital Factorial Randomized Controlled Trial. JMIR Research Protocols. 2025. doi:10.2196/76831
BibTeX
@article{Reisner2025,
author = {Reisner, Sari L and Scheim, Ayden I and Cole, S Wilson and Wirtz, Andrea L and Poteat, Tonia and Mimiaga, Matthew J and Marzinke, Mark A and Meyer, Alek I and Smith, Kevin and Pletta, David R and Mayer, Kenneth H},
title = {Transgender Men and Transmasculine One-on-One and Group-Delivered Empowerment for Targeted HIV Reduction (TOGETHR) Study: Protocol for a Digital Factorial Randomized Controlled Trial},
journal = {JMIR Research Protocols},
year = {2025},
doi = {10.2196/76831}
}
EUVIMED